Multi-component vaccine comprising at least two antigens from
A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae . Such composition comprises at least two different antigens of Haemophilus influenzae , one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. The Haemophilus vaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.
1. An immunogenic composition for conferring protection in a host against disease caused by Haemophilus influenzae , which comprises:
an analog of Haemophilus influenzae Hin47 protein having a decreased protease activity which is less than about 10% of that of natural Hin47 protein, and
a high molecular weight (HMW) protein of a strain of non-typeable Haemophilus influenzae.
2. The composition of claim 1 wherein said HMW protein is present in said composition in an amount which enhances the immune response in the host to the Hin47 protein.
3. The composition of claim 2 wherein said HMW protein is present in the said amount while the individual immunogenicities of the proteins in the composition is not impaired.
4. The composition of claim 1 wherein said analog of Hin47 protein is one in which at least one amino acid of the natural Hin47 protein contributing to protease activity has been deleted or replaced by a different amino acid and which has substantially the same immunogenic properties as natural Hin47 protein.
5. The composition of claim 4 wherein said at least one amino acid is selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein.
6. The composition of claim 5 wherein Serine-197 is replaced by alanine.
7. The composition of claim 5 wherein Histidine-91 is replaced by alanine, lysine or arginine.
8. The composition of claim 7 wherein Histidine-91 is replaced alanine.
9. The composition of claim 5 wherein Asp-121 is replaced by alanine.
10. The composition of claim 3 wherein said HMW protein is an HMW1 or HMW2 protein of a non-typeable strain of Haemophilus influenzae.
11. The composition of claim 10 wherein the HMW1 and HMW2 proteins are produced recombinantly.
12. The composition of claim 10 wherein said HMW1 and HMW2 proteins are derived from the respective strain of non-typeable Haemophilus influenzae and possess respective molecular weights as set forth in the following Table:
Molecular
Non-typeable H. influenzae Strain
Weight (kDa)
12
JoyC
K21
LCDC2
PMH1
15
Mature Protein:
HMW1
125
125.9
104.4
114.0
102.4
103.5
HMW2
120
100.9
111.7
103.9
121.9
13. The composition of claim 1 further comprising an adjuvant.
14. The composition of claim 13 wherein said adjuvant is aluminum hydroxide or aluminum phosphate.
15. The composition of claim 1 comprising
about 25 to about 100 μg of the Hin47 protein analog, and
about 25 to about 100 μg of the HMW protein.
16. The composition of claim 1 further comprising at least one additional antigenic component for conferring protection against infection caused by another pathogen.
17. The composition of claim 16 wherein said at least one additional antigenic component is selected from the group consisting of diphtheria toxoid, tetanus toxoid, pertussis antigens, non-virulent poliovirus and a conjugate of a tetanus or diphtheria toxoid and a capsular polysaccharide of Haemophilus influenzae.
18. The composition of claim 17 wherein said pertussis antigens are selected from the group consisting of pertussis toxoid, filamentous hemagglutinin, pertactin and agglutinogens.
19. A method of immunizing a host against disease caused by infection with Haemophilus influenzae , including otitis media, which comprises administering to the host an immunoeffective amount of the composition as claimed in claim 1 .